A Phase II, Multicenter, Double-blind, Randomized, Placebo Parallel-controlled Trial to Evaluate the Efficacy and Safety of HB0034 in Patients with GPP Presenting with an Acute Flare of Moderate to Severe Intensity
Latest Information Update: 24 Mar 2025
At a glance
- Drugs HB 0034 (Primary)
- Indications Generalised pustular psoriasis
- Focus Therapeutic Use
- Sponsors Huaota Biopharmaceuticals
- 23 Mar 2024 Status changed from not yet recruiting to recruiting.
- 05 Feb 2024 New trial record